Drilldown: Medicines

Other values:

Search

None (26) · Dalmane (1) · Doral (1) · DXM (1) · DXO (1) · Halcion (1) · Lexotan (1) · Librium (1) · Lodine (US brand discontinued); generic (1) · Mogadon (1) · Onfi (1) · ProSom (1) · Relafen (1) · Restoril (1) · Rohypnol (1) · Serax (1) · Spravato (1) · Tranxene (1) · Versed (1) · Xanax (1)

Research material · Classic Psychedelic · Stimulant · Opioid · Sedative-Hypnotic · Phenethylamine · Tryptamine · Benzodiazepine · Botanical · [[:Category:Antihypertensives|Antihypertensive]] · Dissociative · Anticonvulsant · Antidepressant · Plant Medicine · Analgesic · Antiparkinsonian · Antipsychotic · Empathogen · Neuroleptic · Cathinone

Other values:

Search

None (1) · Active metabolite of DXM; NMDA antagonist (1) · Contains salvinorin A (1) · Extremely potent GABAA positive allosteric modulator (1) · GABA-A positive allosteric modulator'"`UNIQ--ref-00000067-QINU`"' '"`UNIQ--vote-00000068-QINU`"' (1) · GABAA positive allosteric modulator (18) · GABAA positive allosteric modulator; low sedation (1) · GABAA positive allosteric modulator; prodrug of desmethyldiazepam (1) · GABAA positive allosteric modulator; very long half-life (1) · Kappa-opioid agonist; NMDA antagonist; SERT/DAT/NET inhibitor (1) · Kappa-opioid receptor agonist (1) · NMDA antagonist (3) · NMDA antagonist; endogenous opioid releaser (1) · NMDA antagonist; fluorinated ketamine analogue (1) · NMDA antagonist; kappa-opioid agonist (1) · NMDA antagonist; ketamine analogue (1) · NMDA antagonist; more stimulating than PCP (1) · NMDA antagonist; opioid agonist (1) · NMDA antagonist; potent opioid agonist (1) · NMDA antagonist; SERT inhibitor; sigma-1 agonist (1) · NMDA antagonist; sigma receptor agonist (2) · NMDA antagonist; sigma receptor agonist; dopaminergic (1) · NMDA antagonist; sigma-1 agonist; serotonin reuptake inhibitor (1) · '"`UNIQ--vote-000011F4-QINU`"' Like all NSAIDs, raises CV thrombotic risk modestly (FDA 2014/2015 advisory) and produces GI, renal, hypertensive, and platelet-inhibitory effects characteristic of the class'"`UNIQ--ref-000011F5-QINU`"'. (1) · '"`UNIQ--vote-00001269-QINU`"' Renal, GI, hypertensive, and CV effects parallel the class profile; modest COX-2 preference may underlie some literature suggesting slightly better GI tolerability than non-selective NSAIDs, though clinically the difference is small'"`UNIQ--ref-0000126A-QINU`"'. (1)

None (41) · Treatment-resistant depression (TRD) in adults, as adjunct to oral antidepressant (FDA-approved March 2019). Depressive symptoms in adults with MDD with acute suicidal ideation or behavior (FDA-approved Aug 2020). (1) · '"`UNIQ--vote-00000069-QINU`"', '"`UNIQ--vote-0000006A-QINU`"', '"`UNIQ--vote-0000006B-QINU`"' (1) · '"`UNIQ--vote-000011F6-QINU`"', '"`UNIQ--vote-000011F7-QINU`"', '"`UNIQ--vote-000011F8-QINU`"' (1) · '"`UNIQ--vote-0000126B-QINU`"', '"`UNIQ--vote-0000126C-QINU`"', '"`UNIQ--vote-0000126D-QINU`"' (1)

None (41) · 0.25 mg (1) · 1000 mg PO once daily; 500-2000 mg/d in single or divided doses (1) · Induction (TRD): 56 mg intranasal twice weekly × 4 weeks. Maintenance: 56-84 mg once weekly × 4 weeks, then 56-84 mg every 1-2 weeks. For acute suicidality: 84 mg twice weekly × 4 weeks. Administered under medical supervision in REMS-certified site. (1) · IR 200-400 mg PO every 6-8 hours; ER 400-1000 mg PO once daily (1)

None (41) · 0.25 mg, 0.5 mg, 1 mg, 2 mg tablets (immediate-release and orally disintegrating); 0.5 mg, 1 mg, 2 mg, 3 mg extended-release tablets; 1 mg/mL oral concentrate (1) · 200, 300, 400, 500 mg IR tablets/capsules; 400, 500, 600 mg ER tablets (1) · 28 mg/device (each dose uses 2 devices) (1) · 500, 750 mg tablets (1)

None (41) · 10 mg/d (1) · 1000 mg/d (osteoarthritis); 1200 mg/d (rheumatoid arthritis) (1) · 2000 mg/d (1) · 84 mg per session (1)

None (41) · Intranasal (under direct medical supervision) (1) · Oral (3)

None (41) · 30-60 min (immediate-release); 1-2 h (extended-release) (1) · Analgesia within 30 minutes; full anti-inflammatory effect over days (1) · Analgesia within hours; anti-inflammatory effect over days (1) · Within hours of first administration (1)

None (41) · 24 hours (1) · 6 h (immediate-release); ~11 h (extended-release) (1) · 6-8 hours (IR); 24 hours (ER) (1) · Acute effect ~24 hours; cumulative effect builds with repeated dosing (1)

None (41) · 11-13 h (immediate-release); 11-16 h (extended-release) (1) · ~24 hours (6-methoxy-2-naphthylacetic acid, the active metabolite)'"`UNIQ--ref-000011F9-QINU`"' (1) · ~7 hours'"`UNIQ--ref-0000126E-QINU`"' (1) · ~7-12 hours (1)

None (41) · 80-90% oral (1) · ~100% (oral; absorption complete)'"`UNIQ--ref-0000126F-QINU`"' (1) · ~38% (oral; non-acidic prodrug improves GI tolerability over many other NSAIDs)'"`UNIQ--ref-000011FA-QINU`"' (1) · ~48% intranasal (1)

None (41) · Avoid after 20 weeks (NSAID-class FDA 2020 advisory on fetal renal injury and oligohydramnios with second/third-trimester use).<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1) · Avoid after 20 weeks (NSAID-class FDA 2020 advisory).<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1) · Avoid; may cause fetal harm (1) · Category D'"`UNIQ--ref-0000006C-QINU`"' (1)

None (41) · Rx, Schedule III (US). REMS program required. (1) · Schedule IV (US) (1) · [[USLegal:Prescription only|Rx-only]] in US. Carries the NSAID-class '''Boxed Warning''' for cardiovascular thrombotic events and serious GI bleeding'"`UNIQ--ref-000011FB-QINU`"' (1) · [[USLegal:Prescription only|Rx-only]] in US. NSAID-class '''Boxed Warning''' for CV thrombotic events and GI bleeding'"`UNIQ--ref-00001270-QINU`"' (1)